Member Contact: Carlos Montagner
Position: Chief Executive Officer
Industry: Biotech & Pharmaceuticals
Specialised Therapeutics Australia (STA) is a biopharmaceutical company dedicated to working with leading pharmaceutical companies worldwide to provide specialised therapies for high unmet medical needs to people living in Australia and New Zealand.
The STA therapeutic portfolio and pipeline at present encompasses oncology and infectious diseases. STA also has interests in other therapies for respiratory, dermatology, endocrinology and central nervous system disorders.
Currently STA has a major focus in oncology, both the treatment and amelioration of side effects associated with many cancer therapies through two leading therapies ABRAXANE® (nanoparticle albumin-bound paclitaxel) and ALOXI® (palonosetron HCl) respectively.